| چکیده انگلیسی مقاله |
Background: Primary percutaneous coronary intervention (PCI) is the gold standard treatment strategy for patients with ST-segment-elevation myocardial infarction (STEMI). In some cases, administration of glycoprotein IIb/IIIa inhibitor, which is regarded as triple antiplatelet therapy (TAPT), is used. Most of the trials that evaluated the role of glycoprotein IIb/IIIa inhibitors in the setting of STEMI were conducted in an era before the use of potent P2Y12 receptor inhibitors. It is reasonable to reevaluate the safety of eptifibatide as a widely used glycoprotein IIb/IIIa inhibitor in patients treated by the last generation of P2Y12 receptor inhibitors, ticagrelor.
Methods: This cross-sectional study was conducted on STEMI patients underwent primary PCI and needed a complementary treatment with eptifibatide during the procedure. Patients were divided into two groups based on the type of P2Y12 receptor inhibitors administered. Eptifibatide had been used for them. Then the safety of the of eptifibatide on top of ticagrelor was evaluated.
Results: 241 patients with the mean age of 57.72 (11.55) were included. Bleeding related to the procedure had no significant difference between the two groups (p=0.641). No major bleeding was observed in both groups. Gastrointestinal bleeding and epistaxis were significantly higher in the ticagrelor-based TAPT group than in the clopidogrel-based group (p=0.033, 0.013, respectively). Genitourinary bleeding was significantly higher in the male subgroup of ticagrelor-based TAPT than in the male subgroup of clopidogrel-based TAPT (p= 0,035).
Conclusion: In patients with STEMI undergoing primary PCI, ticagrelor based-TAPT may significantly increase the risk of minor bleeding events compared with clopidogrel. |
| نویسندگان مقاله |
| Fatemeh Baharvand
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| Zeinab Hasani
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| Seifollah Jafari
Department of Neurosurgery, Road Trauma Research Cenrer, Poursina hospital, School of Medicine, Guilan university of medical Sciences, Rasht, Iran
| Mohammad Esfandiari
Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| Arsalan Salari
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| Motahare Hatami
Tehran heart centre, Tehran university of medical sciences, Tehran, Iran
| Hamed Vahidi
Cardiology Department, ImamKhomeiniHospital Complex, Tehran University of Medical Sciences, Tehran, Iran
| Niloofar Akbari Parsa
Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
| Mahboobeh Gholipour
Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
|